menu
    • menu
    [{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"BioVie","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ BioVie","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ BioVie"},{"orgOrder":0,"company":"NeurMedix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bezisterim","moa":"MAPK3","graph1":"Neurology","graph2":"Phase III","graph3":"NeurMedix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"NeurMedix \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NeurMedix \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by NeurMedix

    Menu

    NeurMedix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : BioVie

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix

                            Details : The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered novel small molecule that inhibits inflammation-driven insulin resistance and major pathological inflamma...

                            Product Name : NE3107

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 06, 2021

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : BioVie

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : BioVie

                            Deal Size : $10.3 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            BioVie Acquires Biopharma Assets from Privately Held NeurMedix

                            Details : NeurMedix’s lead clinical drug candidate, NE3107, 17α-ethynyl-androst-5-ene-3,7,17-triol, is a first-in-class small molecule, orally administered, highly effective inhibitor of insulin resistance and the pathological inflammatory cascade and with a no...

                            Product Name : NE3107

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.3 million

                            April 27, 2021

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : BioVie

                            Deal Size : $10.3 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            NeurMedix

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial

                            Details : The trial will evaluate twice daily 20 mg oral NE3107 versus placebo for 30 weeks beginning with dose titration of 5 mg BID in weeks 1 and 2 and 10 mg BID in weeks 3-4, with 20 mg BID for weeks 5-30.

                            Product Name : NE3107

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 02, 2021

                            Lead Product(s) : Bezisterim

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth